X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs SUVEN LIFE - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA SUVEN LIFE SHASUN PHARMA/
SUVEN LIFE
 
P/E (TTM) x 123.9 19.2 644.3% View Chart
P/BV x 8.5 3.6 239.2% View Chart
Dividend Yield % 0.2 1.1 22.2%  

Financials

 SHASUN PHARMA   SUVEN LIFE
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
SUVEN LIFE
Mar-16
SHASUN PHARMA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs94339 27.8%   
Low Rs46144 31.6%   
Sales per share (Unadj.) Rs214.239.2 545.7%  
Earnings per share (Unadj.) Rs5.37.5 71.5%  
Cash flow per share (Unadj.) Rs15.88.8 180.3%  
Dividends per share (Unadj.) Rs1.002.00 50.0%  
Dividend yield (eoy) %1.40.8 172.7%  
Book value per share (Unadj.) Rs53.349.0 108.9%  
Shares outstanding (eoy) m56.62127.28 44.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.36.2 5.3%   
Avg P/E ratio x13.132.4 40.5%  
P/CF ratio (eoy) x4.427.5 16.1%  
Price / Book Value ratio x1.34.9 26.6%  
Dividend payout %18.726.8 69.9%   
Avg Mkt Cap Rs m3,95830,732 12.9%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m2,164416 519.6%   
Avg. sales/employee Rs ThNM5,236.1-  
Avg. wages/employee Rs ThNM436.5-  
Avg. net profit/employee Rs ThNM995.5-  
INCOME DATA
Net Sales Rs m12,1274,995 242.8%  
Other income Rs m229194 118.5%   
Total revenues Rs m12,3565,189 238.1%   
Gross profit Rs m1,0091,233 81.9%  
Depreciation Rs m594167 355.0%   
Interest Rs m41554 765.9%   
Profit before tax Rs m2301,205 19.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73255 -28.5%   
Profit after tax Rs m302950 31.8%  
Gross profit margin %8.324.7 33.7%  
Effective tax rate %-31.721.2 -149.6%   
Net profit margin %2.519.0 13.1%  
BALANCE SHEET DATA
Current assets Rs m6,8844,986 138.1%   
Current liabilities Rs m8,4561,042 811.3%   
Net working cap to sales %-13.079.0 -16.4%  
Current ratio x0.84.8 17.0%  
Inventory Days Days6261 101.0%  
Debtors Days Days10839 274.8%  
Net fixed assets Rs m4,9703,126 159.0%   
Share capital Rs m113127 89.0%   
"Free" reserves Rs m2,8753,717 77.3%   
Net worth Rs m3,0206,236 48.4%   
Long term debt Rs m1,817432 420.4%   
Total assets Rs m13,3478,079 165.2%  
Interest coverage x1.623.2 6.7%   
Debt to equity ratio x0.60.1 868.1%  
Sales to assets ratio x0.90.6 147.0%   
Return on assets %5.412.4 43.2%  
Return on equity %10.015.2 65.7%  
Return on capital %13.318.9 70.6%  
Exports to sales %46.487.5 53.0%   
Imports to sales %14.212.2 116.5%   
Exports (fob) Rs m5,6224,371 128.6%   
Imports (cif) Rs m1,728611 282.8%   
Fx inflow Rs m5,8434,666 125.2%   
Fx outflow Rs m2,173942 230.7%   
Net fx Rs m3,6693,724 98.5%   
CASH FLOW
From Operations Rs m398922 43.1%  
From Investments Rs m-1,635-619 264.0%  
From Financial Activity Rs m1,309-698 -187.4%  
Net Cashflow Rs m71-396 -18.0%  

Share Holding

Indian Promoters % 39.2 63.4 61.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.0 -  
FIIs % 17.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 36.5 108.5%  
Shareholders   20,750 37,287 55.6%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   GSK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS